Drug intelligence / Profile preview

BNT115

Development stage: Discontinued
Lead developer: BioNTech
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

BNT115 is an investigational **mRNA cancer vaccine** from BioNTech developed within the company's FixVac platform for solid tumors including ovarian cancer. It is a **nucleic acid vaccine** formulated as an RNA-lipoplex designed to deliver mRNA encoding a fixed set of shared, non-mutated tumor antigens to dendritic cells, with the goal of inducing coordinated innate and adaptive antitumor immune responses against cancer cells expressing those antigens. Publicly available information indicates that the program was not approved and its highest reported global development status is discontinued.

Other names: liposome-encapsulated TAAs mRNA vaccine W_ova1

Targets

MAGEA8 (Melanoma-associated antigen 8)

Beyond the preview

Go deeper on BNT115.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BNT115.

Explore the full profile